Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Return on Sales (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Return on Sales for 2 consecutive years, with 0.86% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 704.0% to 0.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.96% through Dec 2025, up 859.0% year-over-year, with the annual reading at 0.96% for FY2025, 859.0% up from the prior year.
  • Return on Sales hit 0.86% in Q4 2025 for Xilio Therapeutics, down from 0.1% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.1% in Q3 2025 to a low of 7.91% in Q4 2024.